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STUDY OBJECTIVES:  
To evaluate the role of orexin-A with respect to cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers, 




Subjects were recruited from multiple community sources for National Institutes of Health supported studies on 
normal aging, sleep and CSF biomarkers. Sixty-three participants underwent home monitoring for sleep-
disordered breathing, clinical, sleep and cognitive evaluations, as well as a lumbar puncture to obtain CSF. 
Individuals with medical history or with magnetic resonance imaging evidence of disorders that may affect brain 
structure or function were excluded. Correlation and linear regression analyses were used to assess the 




Levels of orexin-A, amyloid beta 42 (Aβ42), phosphorylated-tau (P-Tau), total-tau (T-Tau), Apolipoprotein E4 
status, age, years of education, reported total sleep time, number of awakenings, apnea-hypopnea indices (AHI), 
excessive daytime sleepiness, and a cognitive battery were analyzed. Subjects were 69.59 ± 8.55 years of age, 
57.1% were female, and 30.2% were apolipoprotein E4+. Orexin-A was positively correlated with Aβ42, P-Tau, 
and T-Tau. The associations between orexin-A and the AD-biomarkers were driven mainly by the relationship 
between orexin-A and P-Tau and were not influenced by other clinical or sleep characteristics that were available. 
 
CONCLUSIONS:  
Orexin-A is associated with increased P-Tau in normal elderly individuals. Increases in orexin-A and P-Tau 
might be a consequence of the reduction in the proportion of the deeper, more restorative slow wave sleep and 
rapid eye movement sleep reported with aging. 
 
CLINICAL TRIAL REGISTRATION:  
Clinicaltrials.gov registration number NCT01962779.  
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INTRODUCTION: 
The ‘Amyloid Cascade Hypothesis’1 posits that the accumulation and deposition of amyloid beta (Aβ) in the 
brain is the initiating pathological event in Alzheimer’s disease (AD). In humans, a growing body of evidence 
suggests that synaptic activity is associated with increased production of Aβ2-8. During sleep, the brain 
maintains its connectivity during light sleep9-11 but reduces its metabolic and electric activity with increasing 
depth of non REM (NREM) sleep9-13, suggesting that brain soluble Aβ levels may fluctuate with a diurnal 
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pattern consistent with higher neuronal activity during wakefulness and decreased neuronal activity during 
NREM sleep14. Evidence from this Aβ diurnal pattern has been reported in some human studies but not 
others15-19. 
 
Orexin-A (hypocretin 1), a neuropeptide produced by lateral hypothalamic neurons20, is involved in the 
regulation of the sleep-wake cycle by increasing arousal levels21-23 and has been suggested to promote Aβ 
production and amyloid deposition in transgenic mice16. The relationship between the orexinergic system and 
the AD neurodegenerative process in humans has been analyzed by a variety of cross-sectional studies in 
different clinical populations showing so far inconclusive results24-29. Whether increases in Aβ production are 
directly related to orexin-A or are secondary to changes in the sleep-wake cycle is also unknown. 
 
Based on this preliminary evidence, the aims of this study were: (1) to investigate the involvement of the 
orexinergic system in Aβ42 dynamics by measuring cerebrospinal fluid (CSF) orexin-A and AD biomarker 
levels in a large group of non-demented elderly, first globally and then by defining a group of controls and 
increased risk  for AD by their core CSF biomarker profile; (2) evaluate the relationships between the 
orexinergic system and cognition; and, (3) elucidate the role of the orexinergic system, Aβ42 and tau with 
respect to other characteristics of sleep such as total sleep time (TST), number of awakenings, excessive 




67 non-demented elderly were recruited at NYU Center for Brain Health from active National Institutes of 
Health (NIH) supported longitudinal studies of normal aging, Mild Cognitive Impairment (MCI) and CSF 
diagnostic AD-biomarkers that have been ongoing between 1998 and 2015. All subjects agreed to undergo 
additional home monitoring for SDB, a detailed sleep interview and filled out the Epworth Sleepiness Scale 
(ESS)38. Subjects had previously been recruited from multiple community sources including random sampling 
using voter registration records. Individuals with medical conditions or history of significant conditions that 
may affect the brain structure or function, such as stroke, uncontrolled diabetes, traumatic brain injury, any 
neurodegenerative diseases, active major depression, as well as MRI evidence of intracranial mass or infarcts 
were excluded from the parent studies. Sleep complaints were not part of the inclusion or exclusion criteria of 
any of the NIH studies that the subjects were recruited from, nor were subjects referred to the study from the 
NYU Sleep Disorders Clinic that performed the later sleep analyses. 
 
Clinical and diagnostic evaluation 
Subjects received a standardized diagnostic assessment that included medical, psychiatric, and neurologic 
evaluations. The selected subjects were not on active treatment for SDB with CPAP or dental appliances. 
Eligibility requirements for the present study included having had CSF collected from lumbar puncture (LP) 
and a diagnostic structural MRI scan completed prior to the sleep examination (average time interval between 
the sleep study and the lumbar puncture 0.9±1.1 years). Presence of the ApoE4 genotype was determined using 
standard polymerase chain reaction procedures. 
 
Cognitive evaluation 
All subjects were administered a standard neuropsychological test battery, which has published norm 
values30. The measures included subtests of the Guild Memory Scale: verbal paired associates (initial: PRDI, 
delayed: PRDD, and immediate: PARI), delayed paragraph recall subtest (PARD) and the Wechsler Memory 
Scale Revised31: Logical Memory subtests (Logic I and II), to measure declarative memory. Subtests of the 
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Wechsler Intelligence Scale Revised to assess working memory (digits forward: WAISDIG-F and backward: 
WAISDIG-B)32. The Digit Symbol Substitution Test (DSST)32 to evaluate psychomotor speed. Trails A Test to 
evaluate attention and Trails B Test to evaluate executive function33. Category fluency (animals and vegetables) 
and the Boston Naming Test (BNT)34 were used to evaluate language. We subsequently grouped cognitive tests 
into episodic memory: (PARI, PRDI, Logic I, PARD, PRDD, Logic II, DESN) and executive functions 
(WAISDIGB, DSST, category animals and vegetables, TMT B) domains. The score for each domain was an 
average of z-scores of all tests comprised. The average of both domains used was created as a measure of global 




Lumbar punctures were performed between 11:00 AM and 01:00 PM using a 25-gauge needle guided by 
fluoroscopy. All CSF samples were kept on ice until centrifuged for 10 minutes at 1500g, at 4°C. Samples were 
aliquoted to 0.25 mL polypropylene tubes and stored at -80 °C until assayed. CSF was analyzed for Aβ38, Aβ40 
and Aβ42 using the Meso Scale Discovery (MSD) Aβ Triplex assay as described by the manufacturer (MSD, 
Gaithersburg, Md., USA). CSF phosphorylated tau at threonine 181 (P-tau) and total tau (T-tau) were blindly 
analyzed in batch mode using enzyme-linked immunosorbent assays36;37. Orexin-A was measured using an in-
house RIA with minor modifications29. The CSF increased risk for AD group was defined as a CSF P-tau/Aβ42 
ratio ≥0.11, while the control group was defined as a CSF P-tau/Aβ42 ratio< 0.11.  This value was based on a 
separate NYU data set of 171 cognitively normal subjects and 28 AD patients modeled to determine the optimal 
cut-off for diagnostic prediction of AD (data not published). 
 
Sleep Evaluation 
A full sleep evaluation was performed on all subjects, which included a sleep interview, detailed snoring 
history, and self-administration of the ESS38. Home monitoring of SDB was completed using either an ARES 
Unicorder39 or an Embletta MPR40 systems during a 2-night period. The variables collected included were: 1) 
the apnea/hypopnea index with 4% desaturation (AHI4%), defined as the sum of all apneas (>90% reduction 
in airflow for >10 seconds) and all hypopneas (>30% reduction in airflow) associated with >4% O2 desaturation 
divided by the total time where both flow and oximetry signals were valid; 2) the AHIall, which was defined as 
the sum of all apneas and all hypopneas identified divided by the total time where there was a valid flow signal 
irrespective of O2 saturation; and, 3) mean SpO2 saturation during the night. Both systems and AHI indices 
have been compared with the recommended definitions of AHI based on full in laboratory polysomnography 
that included electroencephalogram measures of sleep and show good comparability39;40. Reported total sleep 
time (TST) duration was assessed using one question: ‘During the past month, how many hours of sleep did 
you usually get each night, what is your best estimate’? Sleep fragmentation was assessed using a second 
question. ‘During the past month, how many times do you wake up each night, on average’? 
 
Statistical analysis 
Regression-based z-scores corrected for age, sex, race and education, derived from our normative sample30 
were used for comparisons of cognitive measures with CSF orexin-A values.  The Bonferroni correction was 
used to adjust for multiple comparisons. Non-parametric correlation analyses were used to assess for the 
relations between continuous dependent (CSF AD-biomarkers) and explanatory variables (orexin-A), as well as 
to obtain correlation coefficients. Multiple linear regression were used to create a sleep prediction model for 
Aβ42, P-Tau and T-tau, the AD-biomarker being the dependent variable and orexin-A, AHI4%, AHIall, ESS, 
BMI, age, TST and number of awakenings as independent sleep variables . The linear regression model chosen 
was the one with the highest coefficient of determination (R2) in which all variables maintained a significant 







Demographic characteristics of all subjects (n=67) are shown in Table 1. Subjects were aged 69.8±8.9 years, 
56.7% were female, 30% were ApoE4+.  When comparing CSF defined controls (n=49) with increased risk for 
AD subjects (n=18), statistically significant differences between groups were observed in BMI and presence of 
ApoE4 status. 
 All subjects (n=67) Controls (n=49) Increased risk for AD (n=18) 
Age (y) (mean ± SD) 69.83±8.85 70.74±8.74 67.35±8.94 
Female (%) 56.7% 53.1% 66.7% 
BMI (mean ± SD) 26.64±4.59 25.80±3.98 28.93±5.44* 
Years of education (mean ± SD) 16.49±2.33 16.39±2.42 16.78±2.10 
Hypertension (%) 46.3% 46.9% 44.4% 
Cardiovascular disease (%) 7.5% 8.2% 5.6% 
Diabetes (%) 6.0% 6.1% 5.6% 
Thyroid disease (%) 23.9% 26.5% 16.7% 
Geriatric Depression Score (mean ± SD) 1.99±0.36 1.98±0.38 2.00±0.34 
ApoE4+ (%) 29.9% 20.4% 55.6%** 
Table 1. Abbreviations: BMI, Body Mass Index; ApoE4+, Apolipoprotein E4 positive.  Results are reported in mean ± 
standard deviation. 
CSF AD biomarker levels and orexin-A 
Summary of CSF levels of Aβ38/40/42, P-tau, T-tau and orexin-A are shown in Table 2. When comparing 
CSF defined controls with increased risk for AD subjects using BMI and ApoE4 status as covariates, only CSF 
levels of Aβ42 differed significantly between groups (F=15.7, p<0.01). No other statistically significant 
differences were found between controls and increased risk for AD subjects in any other biomarkers of risk for 
AD or in orexin-A levels.  
 
In all subjects, including the controls and the increased risk for AD groups, significant correlations were 
found between all CSF biomarkers and orexin-A levels (Aβ38: r=0.43, p<0.01; Aβ40: r=0.37, p<0.01; Aβ42: 
r=0.39, p<0.01; P-Tau: r=0.52, p<0.01; T-Tau: r=0.37, p<0.01). Excluding the increased risk for AD subjects 
strengthened all correlations (Aβ38: r=0.49, p<0.01; Aβ40: r=0.46, p<0.01; Aβ42: r=0.53, p<0.01; P-Tau: 
r=0.54, p<0.01; T-Tau: r=0.41, p<0.01). In the increased risk for AD group, there were no significant 
associations between CSF biomarkers and orexin-A, although there was a trend for T-Tau (r=0.46, p=0.052). 
 
In the multiple linear regression models analyses, the best fit sleep model for prediction of  Aβ42 in all 
subjects (controls and increased-risk)  included: orexin-A (β=.34, p<0.01) age (β=.24, p<0.05), BMI (β=-.31, 
p<0.01), and AHI4% (β=.24, p<0.05) (F=8.0, R2=.30, p<0.01). For T-tau, the best fit sleep model included age 
(β=.27, p<0.05), number of awakenings (β=.18, p<0.1) and orexin-A (β=.41, p<.01) (F=7.36, R2=.26, p<0.01). 
For P-Tau no other sleep variables significantly contributed to the model aside from orexin-A.  For the control 
group subjects only, the best fit sleep model for prediction of Aβ42 included orexin-A (β=.64, p<0.01) age 
(β=.26, p<.05), AHIall (β=.28, p<0.05) (F=11.13, R2=.43, p<.01). For P-Tau, the best fit model included orexin 
(β=0.58, p<0.01) and AHIall (β=.22, p<0.1) (F=12.2, R2=.35, p<0.01). For T-tau, the best model included 
orexin-A (β=.51, p<.01) and age (β=.26, p<.05) (F=8.7, R2=.28, p<0.01).  
  
CSF Biomarker All subjects (n=67) controls (n=49) increased risk for AD (n=18) 
Aβ40 5510.43 ± 2132.90 5845.48 ± 2096.32 4598.36 ± 2012.27 
Aβ42 521.80 ± 267.24 612.46 ± 252.08 274.99 ± 98.23** 
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P-Tau 43.67 ± 17.85 42.75 ± 18.41 46.17 ± 16.46 
T-Tau 305.73 ± 142.68 292.01 ± 137.15 343.09 ± 154.63 
Orexin-A 692.18 ± 156.82 696.39 ± 167.00 680.72 ± 128.62 
Table 2. Abbreviations: CSF, Cerebrospinal Fluid; Aβ, amyloid beta; P-Tau, Phosphorylated Tau; T-Tau, Total Tau. 
Results are reported in mean ± standard error. 
 
Figure 1. Scatter plots of CSF Orexin and Aβ38, Aβ40, and Aβ42 with all subjects and with normal subjects only. 
 
Figure 2. Scatter plots of CSF Orexin and P-Tau and T-Tau with all subjects and with normal subjects only. 
Cognition and orexin-A 
Cognitive characteristics of all subjects are shown in Table 3.  All participants had at least 12 years of 
education (mean value: 16.49±2.33) and a MMSE score >26 (mean value: 29.3±1.0).  4 participants had 2 or 
more cognitive test scores 2 standard deviations (SD) below the mean for their age, race, and education-
matched peers.  4 participants were diagnosed as MCI with a Clinical Dementia Rating (CDR) scale of 0.5 by 
the study clinician. When comparing the CSF defined controls with the increased risk for AD subjects using 
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BMI and ApoE4 status as covariates, there were no significant differences in cognitive variables between 
groups.  When comparing all subjects, controls and increased risk for AD groups cognitive scores with orexin-
A levels, the only significant positive correlation found was between orexin-A and Logic II (r=0.28, p=0.024).  
Excluding increased risk for AD subjects strengthened this correlation (r=0.38, p=0.007). Additionally, after 
the increased-risk subjects were excluded, there was a significant positive correlation between orexin-A and 
BNT (r=0.28, p=0.048), and a trend towards lower z-scores on WAISDIG-F (r=-0.29, p=0.052).  Orexin-A 
levels were not significantly correlated to any other cognitive variables, nor were these associations positive 
after adjusting for multiple comparisons in the above analyses.  Moreover, orexin-A levels were not 
significantly correlated to any measure of global cognition (episodic memory, executive function and global 
cognitive function).     
 All subjects Controls  increased risk for AD  
MMSE (raw) 29.22 ± 0.14 29.30 ± 0.15 29.15 ± 0.25 
PRDI (z-scores) 0.47 ± 0.19 0.39 ± 0.19 0.56 ± 0.35 
PRDD (z-scores) 0.63 ± 0.19 0.46 ± 0.20 0.80 ± 0.36 
PARI (z-scores) 0.086 ± 0.14 -0.12 ± 0.15 0.30 ± 0.25 
PARD (z-scores) 0.16 ± 0.14 -0.13 ± 0.14 0.46 ± 0.25 
Logic2 (z-scores) -0.031 ± 0.17 -0.27 ± 0.17  0.21 ± 0.31 
WAISDIG-F (z-scores) -0.34 ± 0.18 -0.088 ± 0.19 -0.60 ± 0.33 
WAISDIG-B (z-scores) -0.31 ± 0.15 -0.23 ± 0.16 -0.39 ± 0.28 
DSST (z-scores) 0.31 ± 0.14 0.30 ± 0.14 0.32 ± 0.25 
Trails A Test (z-scores) -0.31 ± 0.13 0.087 ± 0.14 -0.70 ± 0.25 
Trails B Test (z-scores) -0.22 ± 0.12 -0.027 ± 0.12 -0.41 ± 0.22 
Category fluency animals (z-scores) 0.37 ± 0.14 -0.028 ± 0.14 0.76 ± 0.25 
Category fluency vegetables (z-scores) 0.19 ± 0.15 -0.12 ± 0.15 0.51 ± 0.27 
BNT (z-scores) -0.14 ± 0.14 -0.24 ± 0.14 -0.042 ± 0.26 
Global Episodic Memory (z-scores) 0.30 ± 0.11 0.11 ± 0.11 0.49 ± 0.20 
Global Executive Function (z-scores) 0.068 ± 0.071 -0.036 ± 0.074 0.17 ± 0.13 
Global Cognition (z-scores) 0.16 ± 0.078 0.018 ± 0.079 0.31 ± 0.14 
Table 3. Abbreviations: MMSE, Mini Mental State Examination; PRDI, verbal paired associates initial; PRDD, verbal paired associates delayed; PARI; 
verbal paired associates immediate; PARD, delayed paragraph recall subtest; Logic2, logical memory subtest; WAISDIG-F, digits forward; WAISDIG-B, 
digits backwards; DSST, Digit Symbol Substitution Test; BNT, Boston Naming Test. Results are reported in mean ± standard error 
TST, SDB, ESS and orexin-A 
Summary of objective (AHI4%, AHIall and mean SpO2) and subjective (reported TST, reported number of 
awakening and ESS) sleep indices are shown in Table 4. Among the 67 participants, 22 subjects were 
considered free of SDB (AHI4%<5), 30 had mild SDB (AHI4% 5-14.99), and 15 had moderate to severe SDB 
(AHI4%>15). 8 subjects were considered short sleepers (<6 hours), 41 were normal sleepers (6-8 hours) and 17 
were long sleepers (>8 hours). Only 8 subjects complained of excessive sleepiness (ESS>10). Of all subjects, 4 
were being treated with fluoxetine, 1 was taking bupropion, 2 were taking lorazepam, 1 was taking trazodone, 2 
were taking diazepam and 2 were taking non-prescription sleep medication (melatonin). When comparing CSF 
defined controls with increased risk for AD subjects using BMI and ApoE4 status as covariates, there were no 
significant differences in the sleep variables between groups, although there was an higher number of 
awakenings in the increased-risk for AD group (F=4.1, p<0.05) . In all subjects, as well as in the control or the 
increased risk for AD groups, there were no significant correlations found between orexin-A levels and any of 
the sleep variables.  
Sleep characteristic All subjects Normal  At risk for AD 
TST (mean ± SD) 7.10±1.10 7.14±1.11 6.89±1.16 
Sleep Awakenings (mean ± SE) 1.76±1.38 1.48±1.15  2.31±1.72* 
ESS (mean ± SE) 5.55±3.36 5.67±3.30 5.22±3.59 
AHI4% (mean ± SE) 11.30±12.30 11.26±12.15 11.49±12.85 
AHIall (mean ± SE) 24.20±14.60 23.78±14.73 25.02±14.60 
Mean nocturnal SpO2 (mean ± SE) 94.00%±6.20 94.66%±1.74 94.78%±1.31 
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Table 4. Abbreviations: TST: reported total sleep time; ESS: Epworth sleepiness scale; AHI4%: apnea/hypopnea index with 4% oxygen 
desaturation; AHIall: sum of apneas and hypopneas occurring independent of oxygen desaturation Results are reported in mean ± 
standard error/deviation  
DISCUSSION 
This study is unique in systematically testing multiple CSF AD-biomarkers and comparing them to orexin-A 
levels in a group of non-demented elderly with available objective and subjective measurements of sleep. CSF 
orexin-A levels were positively correlated with Aβ38/40/42, P-Tau and T-tau and the associations were 
strengthened when subjects with a CSF biomarker profile indicative of an increased risk for AD were excluded, 
which suggests that these associations may decrease in the presence of amyloid deposition, axonal 
degeneration or tau pathology.  Including measures of intermittent hypoxia, sleep fragmentation and sleep 
quality such as AHI4%, AHIall or number of awakening increased the AD biomarker prediction models which 
would indicate a more complex modulation of Aβ42 and tau pathology by sleep than previously thought. Less 
than 10% of subjects in this sample were receiving psychotropic medication which may have had influence on 
orexin-A levels or neuronal activity in previous studies. 
 
Previous publications are conflicting with reports of positive or no associations between orexin-A and other 
CSF biomarkers of risk for AD (Table 5). The first study that related CSF Aβ42 to orexin-A was performed in a 
group of six AD patients (mean age 71, range 64-77) and six healthy volunteers (mean age 71, range 59-85)25. 
CSF biomarkers were determined at individual time points with a lumbar catheter during 8 hours.  Orexin-A 
showed a circadian rhythm with amplitude of 11.5 pg/ml that was positively associated with Aβ42 when the 
whole sample (AD and controls) was analyzed. No other analytes were tested. A second study, performed in a 
group of  12 Down syndrome (DS) patients (mean age 41±11) and 20 age-matched controls (mean age 41±15)26, 
also found a positive correlation between orexin-A and Aβ38/40 in both controls and DS patients, while Aβ42 
only correlated with orexin-A in the control group. A correlation of orexin-A with T-tau was also reported in the 
DS group but not in the controls. The third study was performed in a sample of 37 AD patients (mean age 
72.30, range 49.80–89.49), 16 MCI-AD-decliners (mean age 73.20, range 57.39-84.39), 38 other dementias 
(mean age 66.84, range 32.07-85.15) and 15 elderly non-demented controls with narcolepsy-cataplexy (mean 
age 65.59, 54.04-86.38)28.  A positive correlation between orexin-A and Aβ42 was found only in the AD group. 
In contrast, three studies have found associations between orexin-A and tau but not with Aβ42. The first study 
analyzed a group of 48 AD patients and 28 non-demented inpatient controls admitted for suspected 
subarachnoid hemorrhage or chronic polyneuropathy24. CSF orexin-A levels were directly correlated with T-tau 
only in the AD group. The second study included two different groups of AD patients (n=10 and 17, mean age 
66.4±7.2 and 78.8±7.9 respectively) and compared them with two groups of depressed patients in full 
remission (n=10 and 8, mean age 66.3±9.3 and 70.5±6.5 respectively)41. When the whole group was analyzed, 
orexin-A was related with increases in P-Tau/T-Tau and to a lesser extent to Aβ40 but not to Aβ42. The third 
study analyzed a group of 26 AD patients, 18 patients with Lewy Body dementia and 24 non-demented 
controls27. Orexin-A was linked to T-tau in female non-demented controls whereas associations between 
orexin-A and Aβ42 were absent in all groups regardless of gender. Finally, one study performed in a group of 
33 AD patients and 33 healthy volunteers found no significant associations between Aβ42 or tau29. The results 
from the different studies are hard to interpret due to the small sample sizes, heterogeneity of comparison 
groups, presence or absence of psychotropic medication, lack of objective sleep assessments, wide age ranges 
and the possibility that the orexinergic system is affected by the neurodegenerative process itself, as shown by a 
postmortem study that reported a 40% decreased cell number and 14% lower CSF orexin levels in advanced AD 
patients42, which may explain some of the negative findings. Altogether, these results suggest that the 
relationship between orexin-A and AD biomarkers may vary depending on age, clinical diagnoses, sleep 




Author Subjects  n Age Orexin
-A  
Aβ42  Aβ40  Aβ38  P-tau  T-tau 
Slats, D 
(2012) 
AD 6 71  407 Not  
specifie
d † 
n.a n.a n.a n.a 
Outpatient 
controls  
6 71 401 
Assay RIA§ Innobia
§§ 
ELISA§§§ n.a n.a n.a 
Portelius, E 
(2014) 






20 40± 15 716 r=0.56 
†† 
r=0.58 †† r=0.78 
††† 
n.s. n.s. 








Mild AD  21 71.7± 6.3 137.69  n.s n.a n.a. n.s. n.s. 
Moderate 
AD  






15 70.4± 9.9 131.03 n.s n.a n.a. Not rep-
orted 
n.s 




































10 66.3±9.3 238.0 n.s n.s n.a. r= 0.55 
‡ 
n.s 




n.a n.a n.a 
Wennstrom 
M 26 (2012) 
AD patients 26 73±6   n.s. n.a n.a. n.s. n.s. 
DLB 
patients 












Assay  RIA§ n.a n.a n.a n.a n.a 
Dauvilliers 
YA 27 (2014) 
AD patients 37 72.3 451.0 r=0.45, 
†† 
n.a. n.a. n.s. n.s. 
MCI due to 
AD 
16 73.2 503.75 n.s.   n.s. n.s. 
Other 
dementia 
38 66.8 386.0 n.s.   n.s. n.s. 




15 65.6 34.0 n.s.   n.s. n.s. 
Assay RIA§ Innotest 
ELISA§§ 















87.9 n.s.   n.s. n.s. 
Assay RIA§ Innotest 
ELISA§§ 




Table 5. Abbreviations are as follows. AD: Alzheimer’s Disease; DS= Down’s syndrome; n.s.: not statistically significant; n: number of subjects; SD: 
standard deviation; n.a.: not applicable. Age reported as mean age±standard deviation; MCI: mild cognitive impairment; NC: narcolepsy-cataplexy. 
*Control subjects recruited from the Surgical Stress Study, psychiatrically healthy inpatients coming for knee arthroplastic surgery. **Procedures 
performed in an initial “detection” sample and then replicated in the “replication” sample, both samples were distinct from one another ***MDD patients 
drug free except lorazepam, depressed patients were in full remission. †p<0.05 ††p<o.o1 †††p<0.001 ‡0.1>p>0.05 §Radioimmunoassay/Enzyme-linked 
Immunosorbent Assay, Phoenix Pharmaceuticals, Mountain View, CA, USA §§Enzyme-linked Immunosorbent Assay, Innogenetics, Ghent, Belgium §§§ The 
Genetics Company, Schlieren, Switzerland §§§§Meso Scale Discovery Aβ Triplex Assay, Gaithersburg, MD, USA 
 
The clinical relevance of the positive associations we observed between Aβ or tau species with orexin-A in 
non-demented elderly is unknown. Possible explanations for these results include that orexin-A acts directly on 
synaptic activity and remodeling increasing the production of Aβ and tau species prior to neurodegeneration, 
or, that orexin-A may increase AD biomarkers as a result of modulating the sleep-wake cycle by either 
decreasing the total amount of NREM sleep43 or increasing inappropriate transitions between wakefulness, 
NREM and REM44. In a study performed in APP/PS1/OR-/- amyloid transgenic mice, in which the orexin gene 
was knocked out45, loss of orexin resulted in decreased wakefulness and a subsequent reduction in amyloid 
pathology. Focal overexpression of orexin did not alter the amount of Aβ pathology in these mice, while sleep 
deprivation increased the amount of Aβ plaques. These findings support the hypothesis that it is the effects of 
orexin-A on the sleep-wake cycle and not the expression of the neuropeptide itself that modulates Aβ 
pathology. In humans, one postmortem study has verified the coexistence of narcolepsy and AD, which 
demonstrates that AD pathology can also develop in the absence of orexin46 and would support this 
interpretation. Our results, indicating that other sleep characteristics improve the CSF prediction models are 
also in line with these hypotheses. 
 
Limitations of this study include the cross-sectional nature of the findings, the use of a CSF P-tau/Aβ42 
ratio that is laboratory dependent and not generally applicable to other cohorts, and the time interval between 
the sleep studies and the LP.  However, for most key findings, consistent associations where found in the whole 
sample including controls and at increased-risk  groups supporting the main conclusions. Additionally, 
controlling for the time between both procedures did not modify the associations. The results of this study 
should be validated in independent cohorts with in-lab measures of sleep architecture and LPs performed 
immediately after the sleep studies. 
 
In summary, we found evidence that CSF orexin-A levels are positively associated with Aβ, P-tau and T-Tau 
in a group of non-demented elderly.  The strength of the correlations increased when subjects at a theoretical  
increased risk for AD were excluded from the model which indicates that these relationships may be more 
commonly found before the onset of significant plaque pathology or axonal degeneration occur. Including SDB 
indices, and number of awakenings improved the prediction models which suggest a more complex role of 
sleep in AD. 
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